5HT2C Receptor

Cybin One Steps Away From Complete Dosing Cybin (NYSE: CYBN) completed dosing on five of six participant cohorts in its ongoing Phase 2 trial evaluating proprietary deuterated psilocybin analog CYB003 for the treatment of Major Depressive Disorder (MDD). Much like cohort 4, cohort 5 was...